SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing intense selling pressure following a disappointing quarterly forecast, with investors openly questioning the company's long-term growth trajectory and leadership. The community is deeply divided between those calling for a structural 'value trap' exit and others aggressively buying the dip, citing its iconic global brand status as a potential catalyst for a future turnaround.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending as investors weigh mixed sentiment regarding global expansion and beverage partnerships against ongoing concerns about financial performance and potential share dilution. The community remains deeply divided, with some betting on a short squeeze or a potential rebound linked to cannabis rescheduling, while others remain skeptical due to the stock's long-term downward trend.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is experiencing a volatile rally driven by shifting geopolitical narratives surrounding the Iran conflict and anticipation of an upcoming national address from Donald Trump. While bullish traders are betting on a de-escalation, the broader community remains deeply divided, with many debating whether the market is merely witnessing a temporary relief bounce or a sustained reversal amidst continued reports of regional instability and oil supply concerns.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched NASA ETF is generating significant buzz as traders compare its exposure to space-sector heavyweights like SpaceX against other established funds. While many in the community are debating the fund's low initial assets under management and the validity of its holdings, momentum traders are actively discussing its potential for volatility and speculative growth.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest a strong Q4 earnings report and look ahead to the commercial expansion of Yartemlea, with the community actively discussing potential catalysts like upcoming EU regulatory decisions and milestone payments from the Novo Nordisk partnership. While there is significant enthusiasm regarding the long-term potential of the company's pipeline and its transition toward positive cash flow, discourse remains focused on navigating short-term volatility and managing expectations for sales ramp-up.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently experiencing significant downward pressure as investors weigh cooling growth prospects against mounting legal risks stemming from recent court rulings on addictive product design. While some in the community are treating the rapid price pullback as a buying opportunity for long-term AI-driven upside, others are bracing for further volatility due to broader geopolitical tensions and institutional concerns about the company's liability outlook.

Ganymede

Ganymede is gaining attention as community members highlight its clean, controlled price action and steady accumulation patterns. Investors are expressing confidence in the project's current structure, viewing the measured movement as a sign of potential long-term momentum within the broader crypto market.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as investors aggressively debate the company's aggressive Bitcoin acquisition strategy and the impact of recent dilution on shareholder value. Community sentiment is deeply polarized, with bulls viewing the stock as a prime leverage play on Bitcoin's long-term potential, while critics raise concerns over debt levels, the viability of its financing model, and the sustainability of its institutional treasury approach.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as the community doubles down on its "Kendu Unleashed" initiative, promoting a unique, permissionless brand model where holders actively build and launch IRL products ranging from energy drinks to racing gear. Investors are actively discussing the project's long-term conviction and organic growth, frequently highlighting its persistent presence across multiple chains as a key differentiator in the current market.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing heightened investor attention as market participants focus on the company's shift from research and development to commercial execution, underscored by a recent production order and strategic guidance for shipping optical engines. While the community is actively debating the company's manufacturing scalability and the potential for a long-term breakout, sentiment remains mixed between long-term holders tracking partnership integrations and skeptics focused on historical dilution and the lack of immediate revenue scale.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Zynerba Pharmaceuticals Inc

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

ZYNE
Zynerba Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ZYNE News

ZYNEZynerba Pharmaceuticals Inc